Skip to main content
Swing Capital

Sun Pharma Advanced Research Company Ltd

NSE: SPARC BSE: 532872Pharma

Sun Pharma Advanced Research Company Ltd is engaged in the business of research and development (R&D) of pharmaceutical products.[1]

₹162
52W: ₹108 — ₹204
PE 0 · Book ₹10.8 · +1400% vs book
Market Cap₹5,262 Cr
Stock P/E—Price to Earnings
ROCE298%Return on Capital
ROE0%Return on Equity
Div. Yield0%Face Value ₹1

Weaknesses

  • −Company has low interest coverage ratio.
  • −The company has delivered a poor sales growth of -1.35% over past five years.

Shareholding Pattern

Promoters65.67%
FIIs2.04%
DIIs0.88%
Public31.41%
CategoryJun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters65.68%65.68%65.68%65.68%65.67%▼0.065.67%65.67%65.67%
FIIs2.64%2.15%▼0.52.23%▲0.11.45%▼0.81.47%▲0.01.76%▲0.32.04%▲0.32.04%
DIIs0.17%0.21%▲0.00.64%▲0.41.13%▲0.50.97%▼0.21.05%▲0.10.78%▼0.30.88%▲0.1
Public31.51%31.96%▲0.431.47%▼0.531.76%▲0.331.88%▲0.131.52%▼0.431.51%▼0.031.41%▼0.1

Financial Statements

MetricSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales211417171315271088
Expenses1131161241121178981627465
Operating Profit-91-103-108-95-104-74-54-52-66-57
OPM %-432%-740%-649%-566%-808%-499%-198%-543%-838%-673%
Net Profit-86-100-107-97-108-80-61-52-76-81
EPS ₹-2.66-3.07-3.29-2.98-3.32-2.46-1.88-1.6-2.34-2.48

AI Insights

Revenue Trend

TTM revenue at ₹53Cr, down 26.4% YoY. OPM at -431%.

Debt Position

Borrowings at ₹417Cr. Debt-to-equity ratio: N/Ax. High leverage — monitor closely.

Capex Cycle

CWIP at ₹1Cr (1% of fixed assets). Moderate ongoing capital expenditure.

Institutional Flow

DIIs: 0.88% (+0.25pp change). FIIs: 2.04% (-1.60pp change). Promoters hold 65.67%.

Margin & Efficiency

ROCE declining from 21% (Mar 2014) to -298% (Mar 2025). Working capital days: -1778.

Recent Announcements